Acalabrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia and mantle cell lymphoma. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.